A Single Dose Escalation Study of HHT201 in Healthy Subjects - Trial NCT06373094
Access comprehensive clinical trial information for NCT06373094 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Synergy Pharmaceutical Sciences Co., Ltd. and is currently Not yet recruiting. The study focuses on Alzheimer Disease. Target enrollment is 64 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 1
Jun 01, 2024
Mar 31, 2025
Primary Outcome
Adverse events,Number of Participants With Abnormal Laboratory Values,Number of Participants With Abnormal ECG QT Interval,Number of Participants With Abnormal Vital signs,Number of Participants With Abnormal Physical examination,VAS
Summary
The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201
 in healthy subjects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06373094
Non-Device Trial